Tiziana Life Sciences to Ring the Closing Bell at Nasdaq

Rhea-AI Summary

Tiziana Life Sciences (Nasdaq: TLSA) announced that Executive Chairman and Founder Gabriele Cerrone will ring the Nasdaq Closing Bell in Times Square on December 17, 2025 from 3:45 PM to 4:15 PM ET. The ceremony celebrates the company's progress advancing intranasal foralumab, a fully human anti-CD3 monoclonal antibody delivered nasally to target neurodegenerative and inflammatory diseases including multiple sclerosis, Alzheimer's disease, and ALS.

The company noted recent pipeline progress, including dosing the first patient in its Phase 2 Alzheimer's trial, and provided livestream links for the event.

Key Figures

Phase Phase 2 Alzheimer’s clinical trial stage mentioned as recently dosing first patient

Closing Bell time 3:45 PM–4:15 PM ET Scheduled Nasdaq MarketSite closing-bell ceremony window

Market Reality Check

$1.48 Last Close

Volume Volume 252,306 is below the 20-day average of 418,075 (relative volume 0.6x). low

Technical Price $1.55 is trading below the 200-day MA at $1.64, signaling a weaker longer-term trend pre-announcement.

Peers on Argus 1 Down

Peers show mixed moves: SLS up 8.37%, TRDA up 2.9%, VYGR up 1.61%, while KYTX is down 4.3% and appeared in momentum scans with a larger intraday drop, and THRD is slightly down 0.55%. This points to stock-specific rather than broad sector action for TLSA.

Common Catalyst Same-day peer news includes a $100 million equity offering for KYTX and a JPMorgan healthcare conference presentation for TRDA, indicating financing and conference activity across the group rather than a unified catalyst.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 15	Insider share purchase	Positive	-10.7%	CEO disclosed open-market purchase of 163,400 shares increasing total holdings.
Dec 15	Financing update	Neutral	-10.7%	Company withdrew proposed public offering citing market conditions.
Dec 12	Alzheimer’s trial update	Positive	+3.5%	Phase 2 randomized early Alzheimer’s trial began enrollment with dosing expected.
Dec 02	Asset spinout plan	Neutral	+0.0%	Plan to spin out anti-IL-6 asset TZLS-501 into a separate listed company.
Nov 25	ALS trial update	Positive	+5.2%	Intranasal foralumab ALS Phase 2 trial accepted into Healey ALS MyMatch Program.

Pattern Detected

Recent clinically focused releases (ALS and Alzheimer’s trials) saw positive or flat next-day moves, while an insider share purchase coincided with a notable price drop, showing one clear divergence from typically aligned reactions.

Recent Company History

Over the last few weeks, Tiziana reported multiple clinical and corporate updates. On Nov 25, 2025, its intranasal foralumab ALS Phase 2 trial entered the Healey ALS MyMatch Program, followed by a planned spinout of IL-6 asset TZLS-501 on Dec 2. Clinical momentum continued with the Phase 2 Alzheimer’s trial enrollment update on Dec 12. More recently, the company withdrew a proposed offering and disclosed CEO open-market share purchases on Dec 15. Today’s bell-ringing highlights these ongoing developments rather than adding new clinical data.

Market Pulse Summary

The stock moved -5.8% in the session following this news. A negative reaction despite this largely celebratory Nasdaq bell-ringing announcement would fit prior instances where the stock moved counter to seemingly supportive events, such as the -10.67% move following CEO share purchases. With shares already about 40.38% below the 52-week high before this news, broader sentiment, recent offering withdrawal, and clinical execution risk could have outweighed the symbolic nature of the ceremony in the short term.

Key Terms

intranasal foralumab medical

"with its lead development candidate, intranasal foralumab, a fully human, anti-CD3"

Intranasal foralumab is an experimental antibody medication given as a spray or drops into the nose that aims to change how the immune system behaves rather than attack a virus directly. Investors care because results from trials, safety findings, and regulatory decisions determine whether this approach can become a marketed therapy, affecting a company’s future sales, development costs and competitive position — similar to betting on a new product that could reshape a company’s revenue stream.

anti-CD3 monoclonal antibody medical

"intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that"

A lab-made antibody engineered to attach to CD3, a protein found on T cells, so it can change how those immune cells behave. Investors care because these drugs can act like a targeted brake on an overactive immune system—useful for autoimmune disease, transplant rejection or as part of cancer therapies—but they also carry clinical trial, safety and regulatory risks that determine commercial success.

multiple sclerosis medical

"targeting neurodegenerative and inflammatory diseases such as multiple sclerosis,"

A chronic neurological disease in which the immune system damages the protective coating (like insulation on electrical wires) around nerves, disrupting signals between the brain and body and causing symptoms such as numbness, weakness, vision problems, fatigue and mobility issues. It matters to investors because the unpredictability and long-term nature of the condition drive ongoing demand for treatments, influence the value of companies developing therapies, affect healthcare costs and shape regulatory and reimbursement decisions.

Alzheimer's disease medical

"targeting neurodegenerative and inflammatory diseases such as multiple sclerosis, Alzheimer's disease, and ALS."

A progressive brain disorder that slowly erodes memory, thinking and the ability to carry out daily tasks as nerve cells are damaged and lost; symptoms typically worsen over years and can lead to severe impairment. Investors care because it drives a large, growing market for diagnostics, treatments and care services, but also carries high scientific, regulatory and commercial risk—similar to developing a complex new product that must pass difficult safety tests before it can reach patients.

AI-generated analysis. Not financial advice.

BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that Executive Chairman and Founder, Gabriele Cerrone will ring the Closing Bell at the Nasdaq MarketSite in Times Square, New York today.

The ceremony, will be held from 3:45 PM to 4:15 PM ET, celebrates Tiziana's ongoing advancements in innovative treatments, including its lead candidate intranasal foralumab, a fully human anti-CD3 monoclonal antibody. The company's pioneering nasal delivery approach aims to provide improved efficacy, safety, and tolerability compared to traditional intravenous methods, targeting neurodegenerative and inflammatory diseases such as multiple sclerosis, Alzheimer's disease, and ALS.

"This is a proud milestone for Tiziana Life Sciences and a testament to the dedication of our team, partners, and investors," said Gabriele Cerrone, Executive Chairman and Founder of Tiziana Life Sciences. "Ringing the Nasdaq Closing Bell is a powerful celebration of the hard work and dedication of our exceptional team who are tirelessly working to transform patient outcomes through groundbreaking immunomodulation therapies. We are excited about the future as we advance our clinical programs and deliver on our mission to address unmet medical needs."

Tiziana Life Sciences continues to progress its pipeline, with recent achievements including the dosing of the first patient in its Phase 2 Alzheimer's trial and expansions in other key studies.

For more information about the event, visit: https://www.nasdaq.com/events/tiziana-life-sciences-rings-closing-bell

Ceremony Livestream Link: https://www.nasdaq.com/marketsite/bell-ringing-ceremony

About Foralumab

Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 14 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program (NCT06802328) with either an improvement or stability of disease seen within 6 months in all patients. In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis (NCT06292923).

Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative human diseases.^[1],[2]

About Tiziana Life Sciences

Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative intranasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.

For more information about Tiziana Life Sciences and its innovative pipeline of therapies, please visit www.tizianalifesciences.com.

For further inquiries:

Tiziana Life Sciences Ltd
Paul Spencer, Business Development, and Investor Relations
+44 (0) 207 495 2379
email: info@tizianalifesciences.com

[1] https://www.pnas.org/doi/10.1073/pnas.2220272120

[2] https://www.pnas.org/doi/10.1073/pnas.2309221120

FAQ

When will Tiziana Life Sciences (TLSA) ring the Nasdaq Closing Bell?

Tiziana will ring the Nasdaq Closing Bell on December 17, 2025 from 3:45 PM to 4:15 PM ET.

Who will represent Tiziana Life Sciences (TLSA) at the Nasdaq Closing Bell ceremony?

Gabriele Cerrone, Executive Chairman and Founder, will ring the Closing Bell.

What lead candidate did Tiziana Life Sciences (TLSA) highlight during the Nasdaq event?

The company highlighted intranasal foralumab, a fully human anti-CD3 monoclonal antibody delivered nasally.

Which diseases is Tiziana's intranasal foralumab targeting as noted by TLSA?

The company cited targets including multiple sclerosis, Alzheimer's disease, and ALS.

Has Tiziana Life Sciences (TLSA) reported recent clinical progress?

Yes; the company reported dosing the first patient in its Phase 2 Alzheimer's trial.

Where can investors watch the Tiziana Life Sciences (TLSA) Nasdaq Closing Bell livestream?

The ceremony livestream is available via the Nasdaq MarketSite event page and the Nasdaq marketsite bell-ringing webcast link provided by the company.